• LAST PRICE
    1.8150
  • TODAY'S CHANGE (%)
    Trending Down-0.0550 (-2.9412%)
  • Bid / Lots
    1.7400/ 10
  • Ask / Lots
    1.9300/ 12
  • Open / Previous Close
    1.8700 / 1.8700
  • Day Range
    Low 1.8100
    High 1.8950
  • 52 Week Range
    Low 1.0650
    High 6.2801
  • Volume
    419,099
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.87
TimeVolumeMRSN
09:32 ET24661.85
09:34 ET70181.85
09:38 ET27771.85
09:41 ET16801.86
09:48 ET2001.85
09:52 ET108421.845
09:54 ET7001.85
09:56 ET11501.85
09:57 ET20001.85
09:59 ET231481.85
10:01 ET63501.8499
10:03 ET23571.85
10:06 ET7091.85
10:08 ET160431.84
10:10 ET62861.845
10:12 ET30001.86
10:14 ET13001.865
10:15 ET8691.87
10:17 ET12001.8807
10:19 ET15011.895
10:21 ET5001.89
10:24 ET36781.885
10:26 ET3001.885
10:28 ET3001.88
10:30 ET3001.875
10:32 ET8001.86
10:33 ET4001.87
10:35 ET6001.865
10:42 ET7411.86
10:48 ET1001.855
10:50 ET1981.855
11:00 ET223681.85
11:02 ET13671.85
11:04 ET7001.85
11:06 ET6001.85
11:08 ET34271.845
11:09 ET17831.854
11:11 ET4111.855
11:13 ET1001.855
11:20 ET11401.85
11:24 ET17121.855
11:26 ET28301.859
11:27 ET10881.855
11:29 ET5481.855
11:31 ET17881.85
11:33 ET1001.85
11:36 ET1001.85
11:38 ET7001.855
11:47 ET4001.853057
11:49 ET1001.85
11:51 ET1001.85
11:54 ET24821.85
11:56 ET43881.855
11:58 ET98831.8475
12:00 ET84191.85
12:02 ET64001.855
12:03 ET4001.855
12:05 ET23621.86
12:18 ET1001.86
12:20 ET1001.86
12:21 ET58881.87
12:23 ET30861.865
12:27 ET3001.86
12:30 ET1001.86
12:32 ET1001.86
12:34 ET1001.86
12:36 ET14051.864
12:38 ET6001.855
12:41 ET1001.855
12:48 ET1001.855
12:50 ET4071.855
12:52 ET4001.855
12:54 ET151621.84
12:56 ET13001.8475
12:57 ET8681.85
12:59 ET22561.85
01:01 ET15121.85
01:03 ET16001.85
01:10 ET2671.8599
01:14 ET55151.855
01:15 ET3341.855
01:19 ET11001.86
01:24 ET3001.86
01:28 ET1131.87
01:30 ET8001.86
01:32 ET1001.85
01:44 ET2081.85
01:51 ET90451.855
01:53 ET2001.855
01:55 ET15001.86
02:09 ET1001.86
02:13 ET3001.865
02:18 ET1001.865
02:20 ET10401.86
02:27 ET1001.855
02:29 ET2001.85
02:33 ET3001.855
02:36 ET1001.85
02:38 ET218781.85
02:44 ET10521.8508
02:45 ET2001.85
02:51 ET1001.85
02:54 ET3001.85
02:56 ET15471.855
02:58 ET1001.85
03:02 ET2001.85
03:03 ET3391.85
03:05 ET3001.855
03:14 ET2001.855
03:16 ET1961.855
03:23 ET5001.855
03:25 ET2001.855
03:27 ET1001.855
03:30 ET8991.85
03:34 ET1001.84
03:43 ET3171.84
03:45 ET13001.85
03:48 ET3001.845
03:50 ET2851.845
03:52 ET4881.84
03:54 ET7141.845
03:56 ET13001.845
03:57 ET81041.835
03:59 ET979061.81
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMRSN
Mersana Therapeutics Inc
229.4M
-2.1x
---
United StatesNBTX
Nanobiotix SA
201.9M
-3.6x
---
United StatesARTV
Artiva Biotherapeutics Inc
246.5M
0.0x
---
United StatesCRBU
Caribou Biosciences Inc
178.0M
-1.4x
---
United StatesCGEN
Compugen Ltd
146.8M
-14.9x
---
United StatesTCRX
TScan Therapeutics Inc
250.6M
-4.3x
---
As of 2024-10-31

Company Information

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.

Contact Information

Headquarters
840 Memorial DrCAMBRIDGE, MA, United States 02139-3789
Phone
617-498-0020
Fax
302-655-5049

Executives

Independent Chairman of the Board
David Mott
President, Chief Executive Officer, Director
Martin Huber
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Brian Deschuytner
Senior Vice President, Chief Science and Technology Officer
Timothy Lowinger
Senior Vice President, Chief Development Officer
Mohan Bala

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$229.4M
Revenue (TTM)
$29.9M
Shares Outstanding
122.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.47
EPS
$-0.86
Book Value
$0.31
P/E Ratio
-2.1x
Price/Sales (TTM)
7.7
Price/Cash Flow (TTM)
---
Operating Margin
-373.53%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.